Biotech Company Ginkgo To Merge With Harry Sloan-led SPAC in $17 billion deal
By Suzana in Business
Updated 3 years ago
A merger deal will take Boston-headquartered biology building company Ginkgo Bioworks public at a $17 billion equity valuation. The deal, expected to occur in the third quarter this year, is seen to generate up to $2.5 billion in cash proceeds. A synthetic biology pioneer, Ginkgo Bioworks will merge with Soaring...